Exponent vs Forrester Research
EXPO and FORR side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EXPO and FORR compare
Exponent is the larger company, worth 24 times as much as Forrester Research ($4.2B against $174M).
Exponent grew revenue faster over the last twelve months (15.4% versus −7.7% for Forrester Research).
Exponent keeps more of each dollar of sales as profit, with a net margin of 17.4% compared with −12.0% at Forrester Research.
Exponent pays a dividend yielding 1.4%; Forrester Research does not pay one.
Exponent scores higher on the StockData Score (20 against 7 for Forrester Research), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EXPO | FORR |
|---|---|---|
| Size and price | ||
| Market cap | $4.2B | $174M |
| Share price | $87.31 | $9.13 |
| Change, 1 year | 24.4% | 14.8% |
| Change, 5 years | −30.2% | −84.3% |
| Beta (5Y) | 0.87 | 0.95 |
| Employees | 1,313 | 1,474 |
| StockData Score | ||
| Total score | 20 (better) | 7 |
| Valuation score | 2 | 3 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 5 (better) | 0 |
| Health score | 6 (better) | 4 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 37.6× | – |
| P/S | 6.3× | 0.5× (better) |
| P/B | 13.5× | 1.6× (better) |
| EV/EBITDA | 26.8× | – |
| P/FCF | 29.5× (better) | 39.9× |
| PEG | 20.49 | – |
| FCF yield | 3.4% (better) | 2.5% |
| Fair value | $70.23 | $11.66 |
| Margin of safety | −24.3% | 21.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 15.4% (better) | −7.7% |
| Revenue growth, 5Y average | 7.8% (better) | −2.4% |
| Net income growth (TTM) | 9.4% | – |
| EPS growth (TTM) | 13.2% | – |
| EPS growth, 5Y average | 6.0% | – |
| Profitability | ||
| Gross margin | – | 56.9% |
| Operating margin | 21.3% (better) | −13.4% |
| Net margin | 17.4% (better) | −12.0% |
| FCF margin | 21.3% (better) | 1.2% |
| Return on equity | 32.3% (better) | −33.6% |
| Return on invested capital | 51.7% (better) | −37.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.27 (better) |
| Current ratio | 1.93 (better) | 1.02 |
| Altman Z-score | 9.78 (better) | 1.12 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.4% | – |
| Payout ratio | 53.2% | – |
| Years of dividend growth | 13 | – |
| Dividend growth, 5Y average | 9.6% | – |
| Buyback yield | 4.1% | – |
| Shareholder yield | 5.5% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 97.8% | 60.5% |
| Held by insiders | 1.3% | 40.7% |
| Insider net buying, 12 months | −$2.7M | −$199K (better) |
| Short interest, % of float | 5.2% | 4.6% |
Go deeper
- EXPO stock overview
- EXPO income statement
- EXPO valuation and score
- FORR stock overview
- FORR income statement
- FORR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.